West Pharmaceutical
445 hedge funds and large institutions have $10.2B invested in West Pharmaceutical in 2019 Q4 according to their latest regulatory filings, with 90 funds opening new positions, 147 increasing their positions, 143 reducing their positions, and 41 closing their positions.
446% more call options, than puts
Call options by funds: $11.6M | Put options by funds: $2.12M
120% more first-time investments, than exits
New positions opened: 90 | Existing positions closed: 41
15% more capital inflows, than outflows
Capital inflows: $812M | Capital outflows: $706M
10% more funds holding
Funds holding: 406 → 445 (+39)
3% more repeat investments, than reductions
Existing positions increased: 147 | Existing positions reduced: 143
0.28% more ownership
Funds ownership: 91.52% → 91.8% (+0.28%)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$111M |
| 2 |
State Street
Boston,
Massachusetts
|
+$84M |
| 3 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
+$53.9M |
| 4 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$36.9M |
| 5 |
Truist Financial
Charlotte,
North Carolina
|
+$34.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$279M |
| 2 |
Millennium Management
New York
|
-$32.7M |
| 3 |
ExodusPoint Capital Management
New York
|
-$24.8M |
| 4 |
Fisher Asset Management
Camas,
Washington
|
-$24.8M |
| 5 |
JP Morgan Chase
New York
|
-$24.8M |
WST Hedge Fund Activity: Q4 2019 in Review
445 of the 5,094 institutional investors tracked by Wall St. Rank reported a position in West Pharmaceutical (WST) for Q4 2019, worth a combined $10.2B — up 6.7% from $9.57B a quarter earlier.
Buyers outnumbered sellers: 90 funds opened new WST positions and 41 closed out — a net gain of 49 holders — while 147 added to existing stakes and 143 trimmed.
The largest buyer was BlackRock, adding an estimated $111M. The largest seller was T. Rowe Price Associates, cutting an estimated $279M.
- 445 institutional investors held West Pharmaceutical (WST) as of Q4 2019, up from 406 in Q3 2019.
- Funds reported $10.2B of West Pharmaceutical stock for Q4 2019, up 6.7% quarter-over-quarter.
- 90 funds opened new West Pharmaceutical positions in Q4 2019 and 41 closed out, a net change of +49 holders.
- The largest West Pharmaceutical buyer in Q4 2019 was BlackRock, an estimated $111M added.
- The largest West Pharmaceutical seller in Q4 2019 was T. Rowe Price Associates, an estimated $279M sold.
Based on aggregated 13F filings for Q4 2019.